NAC, the GSH precursor, has provided beneficial effects in combating AD pathology through high cytoplasmic cytochrome c release, reduced mitochondrial membrane potential, and reduced Bcl-2 expression, p53 expression and caspase pathways. This evidence concerns the gene BCL2 and Alzheimer disease.